<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072873</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/543/7/21</org_study_id>
    <nct_id>NCT05072873</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women With Twin Pregnancy</brief_title>
  <official_title>The Adjunctive Role of Temporary Uterine Packing Combined With Topical Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women With Twin Pregnancy Undergoing Cesarean Section: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      twin pregnant women requesting cesarean section, the effectiveness and safety of temporary&#xD;
      uterine packing coupled with topical tranexamic acid as an adjuvant for decreasing blood loss&#xD;
      during delivery were compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common cause of postpartum hemorrhage (PPH) is uterine atony, which accounts for up&#xD;
      to 80% of PPH occurrences. PPH is the main cause of maternal morbidity and mortality,&#xD;
      accounting for up to 28% of all maternal deaths globally. As a result, generating a fast and&#xD;
      efficient uterine contraction after birth is critical. Obesity, White or Hispanic&#xD;
      race/ethnicity, polyhydramnios, preeclampsia, anemia, and chorioamnionitis, as well as a twin&#xD;
      pregnancy, are all risk factors for uterine atony.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a double-blind randomized controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>a double-blind randomized controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>30 minutes</time_frame>
    <description>measurement the intraoperative blood loss by direct and gravimetric methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative blood loss</measure>
    <time_frame>12 hours</time_frame>
    <description>measurement the intraoperative blood loss by direct and gravimetric methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of blood transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>number of unites of blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of uterotonic</measure>
    <time_frame>24 hours</time_frame>
    <description>misoprostol, oxytocin etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hemoglobin</measure>
    <time_frame>24 hours</time_frame>
    <description>change in hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Topical tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical tranexamic acid</intervention_name>
    <description>temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid</description>
    <arm_group_label>Topical tranexamic acid</arm_group_label>
    <other_name>experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid</description>
    <arm_group_label>normal saline</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women With Twin Pregnancy Undergoing Cesarean Section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac, hepatic, renal, or thromboembolic disease. ,&#xD;
&#xD;
          -  patients with a high possibility of the morbid adherent placenta,&#xD;
&#xD;
          -  known coagulopathy and&#xD;
&#xD;
          -  those presented with severe antepartum hemorrhage&#xD;
&#xD;
          -  refuse to participate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women With Twin Pregnancy Undergoing Cesarean Section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

